# CUMULATIVE INDEX 2000

## Volume 26

| | |
|---|---|
| February | COMPLEMENTARY AND ALTERNATIVE THERAPIES FOR RHEUMATIC DISEASES II, pages 1–197 |
| May | SYSTEMIC LUPUS ERYTHEMATOSUS, pages 199–413 |
| August | GERIATRIC RHEUMATOLOGY, pages 415–691 |
| November | NEUROENDOCRINE MECHANISMS IN RHEUMATIC DISEASE, pages 693–1042 |

*Note:* Page numbers of article titles are in **boldface** type


Accessory cells, of elderly persons, 462–463
Acetaminophen, in elderly persons, in osteoarthritis, 560–561
N-Acetylcysteine, in SLE, 247
ACTH. See *Adrenocorticotropic hormone.*
Activities of daily living, assessment of, in elderly persons, 420–423
Acupuncture, **103–115**
  contraindications for, 109
  definition of, 104
  efficacy of, 104–105
  in fibromyalgia, 107–108, 112
  in osteoarthritis, 105–107, 110–111
  in rheumatoid arthritis, 108
  philosophy of, 104
  safety of, 108–109
Addison's disease, hyperprolactinemia in, 718
Adhesion molecules, glucocorticoid effects on, 861–862
  of elderly persons, 464
Adrenal gland function, in ankylosing spondylitis, 979–980
  in chronic fatigue syndrome, 992, 996–998
  in fibromyalgia, 993–996
  in inflammation, 702–705
  in rheumatoid arthritis, 788–792
  in Sjögren's syndrome, 929–935, 942
  *Tripterygium silfordii* Hook f effects on, 43–44
Adrenergic receptors, downregulation of, in rheumatoid arthritis, 847–848
Adrenocorticotropic hormone, hyporesponsiveness to, in Sjögren's syndrome, 931
  in elderly persons, in calcium pyrophosphate dihydrate deposition disease, 543
  in gout, 536
  production of, in fibromyalgia, 994–996
  in pregnancy, 807–809
  in rheumatoid arthritis, 150, 153, 155, 814–815
  in Sjögren's syndrome, 930–935
  in stress, 148–149
Advance directives, discussions on, 428–429
Advanced Activities of Daily Living instrument, for elderly persons, 423
Aerobic exercise, for elderly persons, 638–640
Affective status, assessment of, in elderly persons, 425–426
Age, versus bone mass, 572
  versus rheumatoid arthritis incidence, 784–787
Alcohol use, in elderly persons, myopathies induced by, 667
Alcrofenac, in elderly persons, pharmacokinetics of, 446
Alendronate, in osteoporosis prevention and treatment, 320–321, 579–580, 905–906
Allopurinol, in elderly persons, in gout, 538
  pharmacokinetics of, 445

Alpha-linolenic acid, as anti-inflammatory agent, 18
Alternative therapy. See *Complementary and alternative therapy.*
Alveolar hemorrhage, in SLE, cyclophosphamide effects on, 366
Alzheimer's disease, in elderly persons, 425
*Ama* hypothesis, in Ayurvedic medicine, 137
American College of Rheumatology position statement, on complementary and alternative therapy, **190–193**
Amyloid myopathy, in elderly persons, 665–666
Anabolic hormones, in rheumatoid arthritis, bone loss and, 900–901
  replacement of, 903
Androgens. See also *Testosterone.*
  deficiency of, osteoporosis in, 574–575
    rheumatoid arthritis and, 519–520
  glucocorticoid interaction with, 863–864
  in ankylosing spondylitis. See *Ankylosing spondylitis, sex hormones in.*
  in autoimmune disease susceptibility, B lymphocytes, 827–829
    monocytes and macrophages, 831–832
    T lymphocytes, 830
  in rheumatoid arthritis, 812–813
    bone loss and, 899–901, 903
    juvenile, 918
    replacement of, 886–888, 903
  in Sjögren's syndrome, 943
  in systemic lupus erythematosus, 955–956, 960–963
  vascular endothelial system effects of, 768–769
Androstenedione, in juvenile rheumatoid arthritis, 918
Anemia, cyclophosphamide-induced, 367
  hemolytic, in antiphospholipid syndrome, 335
  in elderly persons, in polymyalgia rheumatica, 497
    in systemic lupus erythematosus, 485
Anergy, in elderly persons, 465–466
Angina, in SLE, epidemiology of, 258–259
  risk factors for. See *Atherosclerosis, in SLE, risk factors for.*
Angiogenesis, corticosteroid effects on, 770–771
  estrogen effects on, 767
Ankle, osteonecrosis of, in SLE, treatment of, 302
Ankylosing spondylitis, in pediatric patients, neuroendocrine changes in, 921
  sex hormones in, **969–987**
    androgens, 971–972
    gender differences in, 969–971
    hypotheses not involving, 981–982
    in pregnancy, 971
    levels of, abnormal, 980–981
      adrenal, 979–980
      binding abnormalities and, 977–978
      biologic relevance of, 981
      confounders of, 975–977
      in women, 978–979
      newborn sex ratio and, 972–973
      regulation of, 973–975
    replacement of, 982
Antalarmin, anti-inflammatory activity of, 697–698
Anti-inflammatory agents, plant-based, review of, **13–27**
Antibody(ies), anticardiolipin. See *Anticardiolipin antibodies.*
  antiphospholipid. See *Antiphospholipid antibodies.*
  in SLE, DNA, in apoptosis induction, 219
    inhibitors of, 391–393
  endothelial cell, in apoptosis induction, 219
  interleukin-10, 244
  major histocompatibility complex associations of, 237–238
  model for, 222–224
  osteonecrosis and, 282
  recognizing apoptotic cell surface protein complexes, 218–220
  monoclonal. See *Monoclonal antibodies.*
  production of, androgen effects on, 829
    estrogen effects on, 826–827
  removal of, apheresis in, 64
    rebound of, 67
Anticardiolipin antibodies, as polymyalgia rheumatica markers, 510–511
  in antiphospholipid syndrome, tests for, 336–337
  in SLE, lipid levels and, 266
    osteonecrosis and, 282
Anticoagulants, in SLE, in antiphospholipid syndrome, 342
  in osteonecrosis, 293
Antigens, in SLE, model for, 222–224
  novel fragments of, in apoptosis, 220–221
  overview of, 216–217
  presentation of, defects of, 236–238, 246
  redistribution of, in apoptosis, 217
Antimalarial drugs, in SLE, atherosclerosis development and, 267–268
Antinuclear antibodies, in elderly persons, in systemic lupus erythematosus, 482–483
Antiphospholipid antibodies, in SLE, 208–209, 219
  thrombosis due to, 272

presence of, conditions associated with, 339–340
in asymptomatic persons, 341
versus antiphospholipid syndrome, 332
Antiphospholipid syndrome, in SLE, **331–348**
asymptomatic, 341
classification of, 338–339
clinical features of, 332–336
diagnostic criteria for, 338–339
differential diagnosis of, 339–340
historical aspects of, 331–332
laboratory tests for, 336–337
pregnancy in, 335–336, 342–344
prevalence of, 332
prognosis for, 340–341
treatment of, 341–344
versus antiphospholipid antibody presence, 332
versus primary antiphospholipid syndrome, 337–338
primary, versus antiphospholipid syndrome in SLE, 337–338
Aorta, occlusion of, in antiphospholipid syndrome, 334
Aortitis, giant cell, 501, 505–507
Apheresis, **63–73**
biological effects of, 63–65
complications of, 70–71
extracorporeal photochemotherapy in, 75–81
in Churg-Strauss syndrome, 70
in dermatomyositis, 70
in Guillain-Barré syndrome, 64
in polyarteritis nodosa, 70
in polymyositis, 70
in rheumatoid arthritis, 68–69
in SLE, 65–68
with cyclophosphamide therapy, 371
in thrombotic thrombocytopenia purpura, 70
technology of, 66
Apoptosis, glucocorticoid effects on, 862
in SLE, **215–227**
autoantibodies in, protein complex recognition in, 218–220
autoantigens in, novel fragments of, 220–221
overview of, 216–217
redistribution during, 217–218
cell degradation defects in, 221–222
genes in, 238–239
model of, 222–224
treatment based on, 246
unique events in, 220
of lymphocytes, in photopheresis, 76
Arachidonic acid metabolites, production of, glucocorticoid effects on, 861
Arteritis, giant cell. See *Giant cell (temporal) arteritis.*
Takayasu's, pathogenesis of, estrogen in, 766
versus giant cell arteritis, 502–503
Arthritis, Ayurvedic medicine in, 135–137
pathogenesis of, 137–138
therapies in, 138–140
chronic juvenile. See *Juvenile chronic arthritis.*
collagen-induced, *Tripterygium silfordii* Hook f in, 42–43
crystal-associated. See *Crystal-associated arthritis.*
degenerative. See *Osteoarthritis.*
gouty. See *Gout.*
in SLE, 205–206
in systemic lupus erythematosus, in elderly persons, 477, 484
reactive, hyperprolactinemia in, 719–720
rheumatoid. See *Rheumatoid arthritis.*
Arthritis Impact Measurement Scales, for elderly persons, 421–422
Arthrography, in rotator cuff disease, 596
Arthroplasty, in elderly persons, hip, 603–606
knee, 606–607
shoulder, 607–608
in osteonecrosis, in SLE, 296–297, 300, 302
Arthroscopic surgery, in meniscal injuries, 599
in rotator cuff disease, 597
AS101, in SLE, 396–397
Aspirin, in antiphospholipid syndrome, in SLE, 342–343
in elderly persons, pharmacokinetics of, 446
Association studies, in SLE genetic analysis, 232
Asthma, chiropractic in, 98–99
Atherosclerosis, in SLE, **257–278**
as inflammatory disease, 270–271
assessment of, 209–210
epidemiology of, 258–259
historical observations of, 258
morbidity from, 209
prevention of, 272–274
risk factors for, 263–272
antimalarial therapy, 267–268
corticosteroid therapy, 267
diabetes mellitus, 268
hyperhomocysteinemia, 270
hypertension, 269
lipid abnormalities, 264–269
nontraditional, 263
subclinical, autopsy evidence on, 260
detection of, 259–261
thrombosis in, 271–272
Autoantibodies, in elderly persons, 462
Autoimmune disorders. See also specific disorders.

Autoimmune disorders *(Continued)*
hyperprolactinemia and, 717–719
susceptibility to, sex hormones in, **825–839**
Autonomic nervous system, in juvenile chronic arthritis, 846, 918–920
in rheumatoid arthritis. See *Rheumatoid arthritis, autonomic-neuroendocrine-immune system interactions in.*
Axial myopathies, in elderly persons, 663–664
Ayurvedic medicine, **133–144**
anti-inflammatory agents in, 17, 22
antirheumatic, 138–140
concepts of, 135
future of, 142–143
history of, 133–134
in arthritis, 135–137
pathogenesis of, 137–138
principles of, 134–135
*rasayana* in, 140
validation of, 140–142
Azapropazone, in elderly persons, pharmacokinetics of, 446–447
Azathioprine, in elderly persons, pharmacokinetics of, 444
in SLE, cyclophosphamide with, 370

B lymphocytes, anti-dsDNA antibody downregulation on, in SLE, 392–393
dysfunction of, in SLE, 241, 246–247
of elderly persons, 459–462
sex hormone effects on, 826–829
T lymphocyte interaction with, inhibitors of, in SLE, 390–391
B7 monoclonal antibody, in SLE, 391
Back pain, chiropractic in, 99
herbal preparations in, 15–16, 19–21
Basic calcium phosphate-hydroxyapatite deposition disease, in elderly persons, 543–544
Bcl-2 protein defects, in SLE, 246
Behavioral medicine, 164
Bent spine syndrome, in elderly persons, 663–664
Benzbromanone, in elderly persons, in gout, 538
Bindarit, in SLE, 398
Biofeedback, in rheumatoid arthritis, 165–166, 170–171
Biopsy, temporal artery, in giant cell arteritis, 507–508
Biopsychosocial model of disease, 162–164
Bisphosphonates, in osteoporosis, corticosteroid-induced, 320–321
glucocorticoid-induced, 905–906
in osteoporosis prevention and treatment, 579–580
Blackcurrant seed oil, as anti-inflammatory agent, 15, 18
Bladder toxicity, cyclosphosphamide-induced, 369
Blood loss, in total hip replacement, 604
Bone, growth of, physiology of, 52–54
loss of. See *Osteoporosis.*
metabolic abnormalities of, corticosteroid-induced, 314–315
necrosis of. See *Osteonecrosis.*
remodeling of, osteoporosis and, 571–572
Bone cells, estrogen effects on, 832–834
Bone density measurement, in osteoporosis, 576–577
in SLE, 315–316
Bone grafts, in osteonecrosis, in SLE, 295–296
Bone scan, in osteonecrosis, in SLE, 289–291
Borage seed oil, as anti-inflammatory agent, 15, 18–19
*Boswellia serrata,* in Ayurvedic formulation, as anti-inflammatory agent, 22
Breast-feeding, in rheumatoid arthritis, 806–809
Bromocriptine, in hyperprolactinemia, 723–725
in rheumatoid arthritis, 721
in systemic lupus erythematosus, 72225
in Sjögren's syndrome, 943
in SLE, 244–245, 400–401
Budd-Chiari syndrome, in antiphospholipid syndrome, 333

C-reactive protein, in giant cell arteritis, 510
in polymyalgia rheumatica, 510
Caffeoyl malic acid, in *Urtica dioica,* as anti-inflammatory agent, 23
Calcification, of cartilage, osteoarthritis and, 552–555
Calcitonin, in osteoporosis prevention and treatment, 319–320, 582–583, 906
Calcium, deficiency of, osteoporosis in, 572–573
supplementation with, in osteoporosis prevention and treatment, 317–318, 578, 583
in rheumatoid arthritis, 905
Calcium phosphate-hydroxyapatite deposition disease, in elderly persons, 543–544
Calcium pyrophosphate dihydrate deposition disease (pseudogout), in elderly persons, 538–543
clinical features of, 540

conditions associated with, 540
diagnosis of, 540–542
pathophysiology of, 539
radiography of, 541
treatment of, 543
Camptocormia/cormoptosis, in elderly persons, 663–664
Canale-Smith syndrome, genetics of, 231, 234, 239
Cancer, cyclosphosphamide-induced, 369–370
in elderly persons, myopathies with, 661–662
Capsaicin cream, in osteoarthritis, 561
Caregiver stress, assessment of, 428
Carotid artery, atherosclerosis of, in SLE, assessment of, 209–210, 261–262
Carpal tunnel syndrome, manipulation for, 86
yoga in, 128–129
Cartilage, changes in, osteoarthritis and, 552–555
electromagnetic field effects on, 55–57
glucosamine in, 1–2
growth of, physiology of, 52–54
Catecholamines, deficiency of, in estrogen deficiency, 835
excess of, in juvenile chronic arthritis, 919
in rheumatoid arthritis, 848–849
CD40 ligand monoclonal antibody, in SLE, 390
Celecoxib, in elderly persons, in gout, 536
in osteoarthritis, 562
pharmacokinetics of, 447
Cellular immune response, *Tripterygium silfordii* Hook f effects on, 40
Cellular immunity, of elderly persons, 457–459
in giant cell arteritis, 495–496
Ceramide, in SLE, 246
Chemokine receptor 5 defects, in SLE, 241
Chemotherapy, extracorporeal (photopheresis), 75–81
Chinese medicine, *Tripterygium silfordii* Hook f in, **29–50**
Chiropractic, 92–93, **97–102**
current status of, 98
founding of, 97–98
in asthma, 98–99
in back pain, 99
in headache, 99
insurance issues in, 100–101
mechanisms of action of, 84–86
subsets of, 98
2-Chlorodeoxyadenosine, in SLE, 397
Chloroquine, in elderly persons, in systemic lupus erythematosus, 485
Cholesterol, elevated levels of. See *Hypercholesterolemia.*
Chondrocalcinosis, in calcium pyrophosphate dihydrate deposition disease, 538–539
Chondroitin sulfate, in osteoarthritis, glucosamine with, 8–9
in elderly persons, 562
Chronic fatigue syndrome, neuroendocrine manifestations in, 991–993, 996–998
Chronic juvenile arthritis. See *Juvenile chronic arthritis.*
Churg-Strauss syndrome, apheresis in, 70
Citalopram, in fibromyalgia, 996
Claudication, in antiphospholipid syndrome, 334
Clodronate, in osteoporosis, corticosteroid-induced, 320–321
Clofibrate, in elderly persons, myopathies induced by, 667
Coagulopathy. See also *Thrombosis.*
in SLE, osteonecrosis and, 284–285
Cognitive assessment, of elderly persons, 422, 424–425
Cognitive-behavioral therapy, 164
for fibromyalgia, 168–169
for osteoarthritis, 170
for rheumatoid arthritis, 165–168
in pediatric patients, 169
new developments in, 169–171
Cognitive dysfunction, in antiphospholipid syndrome, 333
in SLE, cyclophosphamide effects on, 365
dehydroepiandrosterone effects on, 356–357
Colchicine, in elderly persons, in calcium pyrophosphate dihydrate deposition disease, 543
in gout, 536–537
myopathies induced by, 667
pharmacokinetics of, 444–445
Collagen, in cartilage, changes in, osteoarthritis and, 552–555
Collagen-induced arthritis, *Tripterygium silfordii* Hook f in, 42–43
Complement, defects or deficiency of, in SLE, 230–231, 234–236, 244
monoclonal antibody treatment of, 245, 393–394
Complementary and alternative therapy, acupuncture, **103–115**
American College of Rheumatology position statement on, **190–193**
apheresis, **63–73**
Ayurvedic medicine, **133–144**
behavioral, **145–159**
chiropractic, 92–93, **97–102**
education, 152–156
electromagnetic fields and magnets, **51–62**
exercise. See *Exercise.*

Complementary and alternative therapy *(Continued)*
glucosamine, **1–11**
homeopathy, **117–123**
ineffective, 191
manual techniques, **83–96**
mind-body medicine, **161–176**
photopheresis, **75–81**
phyto-anti-inflammatory agents, **13–27**
prayer and spirituality, **177–187**
proven, 191
*Tripterygium silfordii* Hook f, **29–50**
types of, 191
unsafe, 191
yoga, **125–132**
Computed tomography, quantitative, in osteoporosis evaluation, 576–577
Coping, with rheumatoid arthritis, spiritual activity effects on, 181
Core decompression, in osteonecrosis, in SLE, 294–295, 299, 302
Coronary artery disease, fibromyalgia with, 676–677
in SLE. See *Atherosclerosis, in SLE.*
Corticosteroids. See also specific drugs.
in antiphospholipid syndrome, in pregnancy, 343
in elderly persons, 656–657
in calcium pyrophosphate dihydrate deposition disease, 543
in giant cell arteritis, 498–499, 508–510
in gout, 536–537
in osteoarthritis, 561
in polymyalgia rheumatica, 498–499
in rheumatoid arthritis, 524
in spinal stenosis, 602
in systemic lupus erythematosus, 484–485
myopathies induced by, 666
pharmacokinetics of, 449–450
in inflammation, 694–695, 702–704
in rheumatoid arthritis. See *Rheumatoid arthritis, glucocorticoid therapy for.*
in Sjögren's syndrome, 942
in SLE, atherosclerosis due to, 267
cyclophosphamide with, 366–367, 370
damage from, 207–208
dehydroepiandrosterone with, 355
osteonecrosis due to, 281–284
osteoporosis due to, 208, **311–329**
resistance to, 864–866
vascular endothelial system effects of, 769–771
Corticotropin. See *Adrenocorticotropic hormone.*
Corticotropin-releasing hormone, deficiency of, in Sjögren's syndrome, 929
production of, estrogen effects on, 834–835
in fibromyalgia, 990–991
in inflammation, 697–698, 703
in pregnancy, 807–809
sex hormone effects on, 863–864
response to, in chronic fatigue syndrome, 996–998
in fibromyalgia, 994–996
in rheumatoid arthritis, 815
Cortisol, deficiency of, in estrogen deficiency, 835
production of, in chronic fatigue syndrome, 992, 996–998
in fibromyalgia, 992–994
in juvenile chronic arthritis, 913–914
in pregnancy, 807–809
in rheumatoid arthritis, 788–789, 862–863
replacement of, in Sjögren's syndrome, 942
Cortisone, in elderly persons, pharmacokinetics of, 449
*CRISP–3* gene, in salivary glands, in Sjögren's syndrome, 937
Cryoglobulinemia, apheresis in, 70
Crystal-associated arthritis, in elderly persons, **527–546**
basic calcium phosphate-hydroxyapatite deposition disease, 543–544
calcium pyrophosphate dihydrate deposition disease (pseudogout), 538–543
gout, 528–538
types of, 527–528
versus rheumatoid arthritis, 522
CTLA–4 monoclonal antibody, in SLE, 390–391
*Curcuma longa*, in Ayurvedic formulation, as anti-inflammatory agent, 22
Currents of injury, in fractures, 54–55
Cushing's disease, vascular endothelial effects of, 769
Cyclooxygenase inhibitors, in elderly persons, pharmacokinetics of, 445–448
*Tripterygium silfordii* Hook f as, 41–42
Cyclophosphamide, in apheresis, 67–68
in elderly persons, in systemic lupus erythematosus, 486
pharmacokinetics of, 442–443
in SLE, **363–375**
apheresis with, 371
clinical studies of, 363–366
drug combinations for, 370
for stem cell transplantation, 371, 379–385
high-dose immunoablative, 371, 383–385
regimens for, 366–367
relapse after, 370–371
toxicity of, 367–370

Cyclosporine, in elderly persons, pharmacokinetics of, 439–440
in rheumatoid arthritis, 887
in Sjögren's syndrome, 943
Cysteamine, in SLE, 247
Cystitis, cyclosphosphamide-induced, 369
Cytapheresis. See *Apheresis.*
Cytokines. See also specific cytokines.
autonomic effects of, in juvenile chronic arthritis, 919–920
hepatic effects of, 701–702
in bone loss, in rheumatoid arthritis, 899
in hypothalamic-pituitary-adrenal axis activation, 702–704
in osteoarthritis pathogenesis, 557
inhibitors of, in SLE, 394–395
of elderly persons, 463–464
production of, androgen effects on, 828–830
estrogen effects on, 767, 826–827, 833–834
glucocorticoid effects on, 860–861
gonadotropin-releasing hormone in, 726
in inflammation, 694
in pregnancy, 807–809
in rheumatic disease, 912–914
in rheumatoid arthritis, 884–885
in Sjögren's syndrome, 934
proinflammatory, 696–697
removal of, apheresis in, 65
*Tripterygium silfordii* Hook f effects on, 40

Dapsone, in elderly persons, 485–486
Deflazacort, in rheumatoid arthritis, 904
Degenerative arthritis. See *Osteoarthritis.*
Dehydroepiandrosterone and dehydroepiandrosterone sulfate, in ankylosing spondylitis, 972, 976, 979–981
in rheumatic disease, 887
in rheumatoid arthritis, 787–790, 812–815
bone loss and, 899–901
juvenile, 918
in Sjögren's syndrome, 936
in SLE, 244–245, **349–362,** 399–400, 963
adverse effects of, 355–356
clinical trials of, 353–358
future directions of, 358–359
over-the-counter, 359
physiology of, 349–351
rationale for, 351–353
production of, in inflammation, 703–704
in pregnancy, 807–809
uses of, 359–360
Delirium, in elderly persons, 424–425
Dementia, in antiphospholipid syndrome, 333
in elderly persons, 424–425
Depression, in chronic fatigue syndrome, 996
in fibromyalgia, 993–994
in rheumatic disease, 171
in Sjögren's syndrome, 929
Dermatomyositis, apheresis in, 70
in elderly persons, 658–662
DHEA. See *Dehydroepiandrosterone and dehydroepiandrosterone sulfate.*
Diabetes mellitus, in SLE, atherosclerosis in, 268
Diclofenac, in elderly persons, pharmacokinetics of, 446
Diet, in Ayurvedic medicine, 138–139
Diflunisal, in elderly persons, pharmacokinetics of, 446
Diuretics, gout due to, 533–534
in osteoporosis, corticosteroid-induced, 318
DNA, antibodies to, in SLE, in apoptosis induction, 219
inhibitors of, 391–393
DNase, in SLE, 393
Doppler studies, in atherosclerosis, in SLE, 209–210
*Doshas,* in Ayurvedic medicine, 134–135, 137–138
Drop arm test, in rotator cuff disease, 596
Dropped head syndrome, in elderly persons, 664
Drugs, for elderly persons, **433–454**
absorption of, 435
acetylator phenotype and, 443–444
albumin binding of, 436
allopurinol, 445
area under the concentration-time curve for, 435
azathioprine, 444
colchicine. See *Colchicine.*
corticosteroids. See *Corticosteroids.*
cyclophosphamide, 442–443, 486
cyclosporine, 439–440
distribution of, 435–436
etanercept, 448
fibromyalgia associations with, 677–678
hydroxychloroquine, 444, 485, 543
leflunomide, 442
metabolism of, 436–438
methotrexate, 440–442, 499
myopathies induced by, 666–667
nonsteroidal anti-inflammatory drugs. See *Nonsteroidal anti-inflammatory drugs.*
pharmacodynamics of, 435
pharmacokinetics of, 434–439
prescription of, 450–451
renal elimination of, 438–439
sulfasalazine, 443
tumor necrosis factor inhibitors, 448–449

Drugs *(Continued)*
use of, assessment of, 427
volume of distribution of, 434
SLE due to, 203
Dual-energy x-ray absorptiometry, in osteoporosis, 576–577
in SLE, 315–316
Duplex scans, in atherosclerosis, in SLE, 209–210

3E10 therapy, for SLE, 392
Economic effects, of mind-body medicine, 171
Edema, in remitting seronegative symmetrical synovitis, versus rheumatoid arthritis, 522–523
Education, in rheumatoid arthritis, 152–156, 165–167
Elbow, epicondylitis of, herbal preparations in, 21
Elderly persons, arthroplasty in, hip, 603–606
knee, 606–607
shoulder, 607–608
assessment of, **415–432**
advance directives, 428–429
affective, 425–426
cognitive, 422, 424–425
definition of, 416–417
efficacy of, 418–419
functional, 420–423, 624–625
in caregiver stress, 428
medication, 427
nutritional, 426–427
setting for, 417–418
social, 427–428
ten commandments for, 429–431
crystal-associated arthritis in, 522, **527–546**
diffuse pain syndromes in, **673–682**
fitness exercise prescription for, **617–646**
fractures in, 575, 608–613
giant cell arteritis in. See *Giant cell (temporal) arteritis.*
immune function in, **455–473,** 518–519
lumbar stenosis in, 599–603
meniscal injuries in, 598–599
myopathies in, **647–672**
orthopedic problems in, **593–616**
osteoarthritis in. See *Osteoarthritis.*
osteoporosis in. See *Osteoporosis, in elderly persons.*
pharmacologic considerations in, **433–454**
polymyalgia rheumatica in, 493–500, 510–511, 679
rheumatoid arthritis in, **517–526,** 618–624
rotator cuff disease in, 593–597
systemic lupus erythematosus in, **455–473**
Electric stimulation, in osteonecrosis, in SLE, 292
Electromagnetic fields, in musculoskeletal disorders, **51–62**
background of, 52–54
cartilage effects of, 55–57
clinical applications of, 57–58
currents of injury in, 54–55
in fractures, 54–55
safety of, 59–60
Electromyography, in myopathies, in elderly persons, 652–653
Embolism, pulmonary, in antiphospholipid syndrome, treatment of, 344
End-of-life care, discussions on, 428–429
Endorphins, anti-inflammatory activity of, 699
Endothelium. See also *Vascular endothelial system.*
antibodies to, in SLE, in apoptosis induction, 219
Environmental factors, in SLE, 203
osteoporosis in, 312
Epicondylitis, herbal preparations in, 21
Epinephrine, in inflammation, 844
Epitriptriolide, 31
Erythrocyte sedimentation rate, in giant cell arteritis, 504
in polymyalgia rheumatica, 493, 497
Estrogen receptor modulators, in SLE, 400
Estrogen(s), deficiency of, osteoporosis in, 573–574
rheumatoid arthritis and, 519–520
elevated levels of, in SLE, osteoporosis in, 312–313
environmental, 883–884
glucocorticoid interaction with, 863–864
in ankylosing spondylitis. See *Ankylosing spondylitis, sex hormones in.*
in autoimmune disease susceptibility, B lymphocytes, 826–827
bone cells, 832–834
indirect effects of, 834–835
monocytes and macrophages, 830–831
T lymphocytes, 829–830
in fibromyalgia, 995
in gonadotropin-releasing hormone production and action, 727
in pregnancy, 807–809
in prolactin production, 716–717
in rheumatoid arthritis, 810–812
bone loss and, 901–903
juvenile, 917–918
in Sjögren's syndrome, 934–938
in systemic lupus erythematosus, 952–953, 956–960, 962–963
juvenile, 921

replacement of, in osteoporosis prevention and treatment, 318–319, 578–579
in rheumatoid arthritis, 888–889, 902–903
vascular endothelial system effects of, 766–768
Etanercept, in elderly persons, pharmacokinetics of, 448
Etidronate, in osteoporosis prevention and treatment, 320–321, 582
Etodolac, in elderly persons, pharmacokinetics of, 446
Evening primrose oil, as anti-inflammatory agent, 15, 18
Exercise, bone growth in, 53
for elderly persons, **617–646**
aerobic, 638–640
assessment for, 625, 630–633
benefits of, 618
biologic aspects of, 624–625
goals of, 625
in osteoarthritis, 558–559, 624, 626–629
in osteoporosis prevention and treatment, 577–578
in rheumatoid arthritis, 618–624
isometric, 635–636
isotonic, 636–638
lack of, sarcopenia in, 648–649
patient education for, 630–631
patient participation in, 632–633
prescription for, 630–633
principles of, 631–632
psychologic aspects of, 624–625
sociologic aspects of, 624–625
strengthening, 635–638
stretching, 634
in rheumatoid arthritis, 152–156, 165, 618–624
Exotoxin, hormone suppression by, 703
Extracorporeal chemotherapy (photopheresis), 75–81
Eye, autoimmune disease of, hyperprolactinemia in, 718–719

Facioscapulohumeral dystrophy, in elderly persons, 662
Family, participation in mind-body medicine, 170
Fas protein, defects of, in SLE, 231, 234, 239, 246
Fat, pathology of, in osteonecrosis, in SLE, 293
Fc receptors, defects of, in SLE, 236
Femoral head, osteonecrosis of. See *Hip, osteonecrosis of.*
Fenbufen, in elderly persons, pharmacokinetics of, 446
Fenoprofen, in elderly persons, pharmacokinetics of, 446
Fever, in giant cell arteritis, 501
modulation of, 702
Feverfew, as anti-inflammatory agent, 16, 20–21, 24
Fibrinogen, elevated levels of, in SLE, 271–272
Fibromyalgia, acupuncture in, 107–108, 112
cognitive-behavioral therapy for, 168–169
homeopathic treatment of, 119–121
hypothalamic-pituitary-adrenal axis hyperfunction in, 993–996
in elderly persons, 673–679
clinical features of, 674–679
definition of, 673
differential diagnosis of, 679–681
epidemiology of, 673–674
versus polymyalgia rheumatica, 498, 679
in SLE, 210–211
mind-body medicine in, 163
stress and, 749–751, 754–755, 990–991
Ficat and Arlet system, for osteonecrosis staging, 287
Finger(s), gout of, 531–532
Fisher-Evans syndrome, in antiphospholipid syndrome, 335
Flare, in SLE. See *Systemic lupus erythematosus, flare in.*
Flexibility exercises, for elderly persons, 633–634
Fludarabine, in SLE, cyclophosphamide with, 370
Fluoride supplementation, in osteoporosis, glucocorticoid-induced, 906
Flurbiprofen, in elderly persons, pharmacokinetics of, 446
Follicle-stimulating hormone, in juvenile chronic arthritis, 917
in juvenile systemic lupus erythematosus, 920–921
in testosterone regulation, 975
Fractures, currents of injury in, 54–55
healing of, physiology of, 52–54
in elderly persons, 570–571, 575, 608–613
in rheumatoid arthritis, 897–898, 904
*Fraxinus excelsior*, in Phytodolor, 16–17, 21–22
FTY720, in SLE, 246
Functional Activities of Daily Living instrument, for elderly persons, 423
Functional assessment, of elderly persons, 420–423, 624–625

Gamma globulin, in antiphospholipid syndrome, in pregnancy, 343

Gamma-linolenic acid, as anti-inflammatory agent, 18
Gangrene, in antiphospholipid syndrome, 334
Gastrointestinal vasculitis, in SLE, cyclophosphamide effects on, 366
Gender differences, in gonadotropin-releasing hormone production and action, 727–728
in rheumatic diseases, 969–971
in rheumatoid arthritis, 784–787
in Sjögren's syndrome, 936–938
in SLE, 200–201, **951–968**
androgen metabolism and, 352
genetic aspects of, 241–242
in osteonecrosis, 280
Gene therapy, for SLE, 395
Genetics, of rheumatoid arthritis, 778, 783–784, 786–787
in elderly persons, 519
of SLE, **229–256**
analysis of, association studies in, 232
goals of, 230–231
linkage analysis in, 232–233
pathologic, 234
antigen presentation and, 236–238
apoptosis and. See *Apoptosis.*
B-cell tolerance and, 241
complement defects and, 230–231, 234–236
cytokines and, 238–241
Fc receptor defects and, 236
gender and, 241–242
glutathione-S-transferase defects and, 242, 247
immune complex clearance and, 234–236
linkage studies in, 242–243
polygenic effects in, 231–232
single gene effects in, 230–231
T-cell tolerance and, 238–241
treatment strategies and, 243–247
Geriatric rheumatology. See *Elderly persons.*
Geropharmacology. See *Drugs, for elderly persons.*
Giant cell (temporal) arteritis, in elderly persons, atypical presentation of, 501–502
autoimmune aspects of, 495
classification criteria for, 503
clinical features of, 500–507
diagnosis of, 497–498, 507–508
epidemiology of, 500
markers of, 510–511
pathophysiology of, 494–497
polymyalgia rheumatica with, 494, 497
prognosis for, 511
treatment of, 498–499, 508–510
Glenohumeral joint, replacement of, in elderly persons, 607–608
Glomerulonephritis, in systemic lupus erythematosus, in elderly persons, 486
Glucocorticoids. See *Corticosteroids.*
Glucosamine, in osteoarthritis, **1–11**
buyer cautions with, 9–10
chondroitin sulfate with, 8–9
clinical trials of, 3–8
in elderly persons, 562
mechanism of action of, 1–2
pharmacokinetics of, 2
Glutathione-S-transferase, SLE and, 242, 247
Gonadal dysfunction, corticosteroid-induced, osteoporosis in, 314
Gonadotropin-releasing hormone, 725–728
autoimmune disease and, 726–727
gender differences in, 727–728
immune actions of, 726
Gout, in elderly persons, 528–538
acute, 535–537
atypical tophaceous, 532–533
chronic, 537–538
clinical features of, 529–534
diagnosis of, 534
differential diagnosis of, 534–535
diuretic-induced, 533–534
epidemiology of, 528–529
female, 530–531
in finger joints, 531–532
intercritical, 529, 537
polyarticular, 530
radiography in, 534
treatment of, 535–538
versus calcium pyrophosphate dihydrate deposition disease, 540
Granulocytapheresis, in rheumatoid arthritis, 68–69
Growth hormone, excess of, corticosteroid-induced, osteoporosis in, 315
production of, in juvenile chronic arthritis, 916–917
replacement of, in osteoporosis, corticosteroid-induced, 323
Guillain-Barré syndrome, apheresis in, 64

Hair dyes, SLE and, 203
*Harpagophytum* extract, as anti-inflammatory agent, 15–16, 19–20, 24
Hatha yoga, 126
in osteoarthritis, 127–128
prospective controlled studies of, 128–129
styles of, 126–127
Headache, chiropractic in, 99
in giant cell arteritis, 501, 504
Healing, of bone, physiology of, 52–54
religious beliefs and, 178–179
Health Assessment Questionnaire, for elderly persons, 420–421

Health status, assessment of, in SLE, 210–211
Heart, valvular lesions of, in antiphospholipid syndrome, 336
Hematopenia, in systemic lupus erythematosus, in elderly persons, 477
Hematopoiesis, in elderly persons, 456–457
Hematopoietic stem cell transplantation. See *Stem cell transplantation.*
Hemochromatosis, calcium pyrophosphate dihydrate deposition disease in, 539
Hemolytic anemia, in antiphospholipid syndrome, 335
in systemic lupus erythematosus, in elderly persons, 485
Heparin, in antiphospholipid syndrome, in pregnancy, 343
Herbal preparations, anti-inflammatory, review of, **13–27**
in Ayurvedic medicine, 138–140
*Tripterygium silfordii* Hook f, **29–50**
Hereditary inclusion body myopathies, in elderly persons, 655–658
Hip, disorders of, in elderly persons, dislocation after replacement, 606
fractures, 570–571, 608–610
replacement in, 603–606
osteonecrosis of, in SLE, coagulopathy in, 284–285
corticosteroid-induced, 282–284
diagnosis of, 285–291
incidence of, 280
pathogenesis of, 280
pathology of, 280–281
risk factors for, 281–285
treatment of, 292–298
Homeopathy, **117–123**
clinical trials of, 118–122
history of, 118
Homocysteinemia, elevated levels of, in SLE, 270
Hopkins Lupus Cohort, **199–213**
damage in, 206–210
disease activity in, 203–204
environmental triggers in, 203
epidemiology in, 199–203
evolution in, 204–205
health status in, 210–211
organ system involvement in, 205–206
Hormones. See also *Neuroendocrine manifestations; Sex hormones;* specific hormones.
in SLE, abnormalities of, corticosteroid-induced, osteoporosis in, 312–314
gender differences in, 352
genetic aspects of, 241–242
replacement of, 398–401. See also *Dehydroepiandrosterone and dehydroepiandrosterone sulfate.*
in osteoporosis, corticosteroid-induced, 318–319
stress, immunity and, 148–149
Hughes syndrome. See *Antiphospholipid syndrome.*
Human leukocyte antigens, in giant cell arteritis, 495
in polymyalgia rheumatica, 495
in SLE, 236–238
Humerus, fractures of, in elderly persons, 611–612
Humoral immunity, of elderly persons, 459–462
in systemic lupus erythematosus, 479–483
*Tripterygium silfordii* Hook f effects on, 40–41
Hyaluronic acid, in cartilage, changes in, osteoarthritis and, 552–555
injections of, in osteoarthritis, 561
Hydrocortisone, in chronic fatigue syndrome, 998
Hydroxychloroquine, in antiphospholipid antibodies, 341
in elderly persons, in calcium pyrophosphate dihydrate deposition disease, 543
in systemic lupus erythematosus, 485
pharmacokinetics of, 444
in SLE, atherosclerosis development and, 267
16a-Hydroxyestrone, in systemic lupus erythematosus, 959–961
17a-Hydroxyprogesterone, in ankylosing spondylitis, 979
Hypercholesterolemia, in SLE, 264–269
treatment-induced, 267–268
untreated, 266–267
with diabetes mellitus, 268
Hyperhomocysteinemia, in SLE, 270
Hyperlipidemia, in osteonecrosis, in SLE, 293
Hyperparathyroidism, calcium pyrophosphate dihydrate deposition disease in, 539
osteoporosis in, 572–573
Hyperprolactinemia, in ankylosing spondylitis, 921
in autoimmune disease, 717–719, 728–729, 939
in juvenile chronic arthritis, 914–915
in rheumatic disease, 719–724
in rheumatoid arthritis, 809–810
in Sjögren's syndrome, 940–941, 943
in systemic lupus erythematosus, 960–961
juvenile, 920
treatment of, 724–725
Hypersensitivity, delayed-type, in elderly persons, 465–466
Hypertension, as atherosclerosis risk factor, in SLE, 269

Hyperthyroidism, myopathies in, in elderly persons, 665
Hypertriglyceridemia, in SLE, 266
Hyperuricemia. See also *Gout.*
epidemiology of, 528–529
Hypogonadism, osteoporosis in, 574–575
Hypomagnesemia, calcium pyrophosphate dihydrate deposition disease in, 539
Hypophosphatasia, calcium pyrophosphate dihydrate deposition disease in, 539
Hypothalamic-pituitary-adrenal axis, estrogen effects on, 834–835
in chronic fatigue syndrome, 992, 996–998
in fibromyalgia, 993–996
in inflammation, 702–705
neuroendocrine-immune loop concept and, 705–708
in rheumatoid arthritis, 150, 813–814, 849–850, 935
juvenile, 913–914
in Sjögren's syndrome, 929–935, 942
sex hormone effects on, 863–864
sympathetic-adrenal-medullary system interactions with, 147–148
*Tripterygium silfordii* Hook f effects on, 43–44
Hypothalamic-pituitary-gonadal axis, in juvenile rheumatoid arthritis, 917–918
in Sjögren's syndrome, 934–938
in systemic lupus erythematosus, 920–921
Hypothalamic-pituitary-thyroid axis, in Sjögren's syndrome, 934, 938–941
Hypothalamus, in fever modulation, 702
Hypothyroidism, in Sjögren's syndrome, 939–941
myopathies in, in elderly persons, 664–665

Ibuprofen, in elderly persons, in osteoarthritis, 561
pharmacokinetics of, 446
in osteoarthritis, versus glucosamine, 6–8
Imagery, in rheumatoid arthritis, 165
Immune complexes, circulating, removal of, apheresis in, 65
in SLE, clearance defects in, 234–236, 244–246
Immune system, androgen effects on, 955–956
estrogen effects on, 834–835, 956–957
in rheumatoid arthritis. See *Rheumatoid arthritis, autonomic-neuroendocrine-immune system interactions in.*
neuroendocrine system interactions with, in inflammation. See *Inflammation, neuroendocrine-immune system interactions in.*
in stress, 756–757
of elderly persons, **455–473**
accessory cells, 462–463
adhesion molecules, 464
B lymphocytes, 459–462
clinical aspects of, 465–466
cytokines, 463–464
hematopoiesis, 456–457
rheumatoid arthritis and, 518–519
systemic lupus erythematosus and, 479–482
T lymphocytes, 457–459
telomere senescence, 464–465
thymus, 457
progesterone effects on, 957–958
stress hormones effects on, 148–149
*Tripterygium silfordii* Hook f effects on, 40–41
Immunodeficiency, cyclophosphamide-induced, 368
Immunoglobulin G, selective removal of, in rheumatoid arthritis, 69
Immunoglobulin(s), intravenous, in antiphospholipid syndrome, in pregnancy, 343
in SLE, 391–392
of elderly persons, 459–462
production of, androgen effects on, 827–828
estrogen effects on, 826–827
Immunosuppressive therapy, for myopathies, inclusion body, 656–657
Inclusion body myopathies, in elderly persons, 655–658
India, Ayurvedic medicine origin in, 133–134
yoga origin in, 125
Indomethacin, in elderly persons, in gout, 536
pharmacokinetics of, 446
Infections, cyclophosphamide-induced, 368
glucocorticoid-induced, 871–872
in elderly persons, in polymyalgia rheumatica pathogenesis, 496–497
in total hip replacement, 605–606
in total knee replacement, 607
versus diffuse pain syndromes, 680
Infertility, in antiphospholipid syndrome, 336
Inflammation, atherosclerosis in, in SLE, 270–271
enzymes promoting, glucocorticoid effects on, 861
hypothalamic-pituitary-adrenal axis in, neuroendocrine-immune loop concept and, 705–708

in rheumatoid arthritis, regulation of. See *Rheumatoid arthritis, autonomic-neuroendocrine-immune system interactions in.*
neuroendocrine system-immune system interactions in, **693–711**
anti-inflammatory immune components in, 698–699
anti-inflammatory neuroendocrine-derived components in, 699
consequences of, 700–701, 704
corticosteroids in, 704
hepatic function alterations in, 701–702
hypothalamic-pituitary-adrenal axis in, 704–705
in local acute-phase response, 696–701
in systemic acute-phase response, 701–708
neuroendocrine-immune loop concept in, 695–696, 705–708
neuroendocrine system activation in, 702–704
overview of, 693–696
proinflammatory cytokines in, 696–697
proinflammatory neuroendocrine factors in, 697–698
pathogenesis of, vascular endothelial system in, **765–773**
Inflammatory mediators, *Tripterygium silfordii* Hook f effects on, 41–42
Inflammatory myopathies, in elderly persons, 654–662
Infliximab, in elderly persons, pharmacokinetics of, 448
Injury currents, in fractures, 54–55
Instrumental Activities of Daily Living instrument, for elderly persons, 423
Insulin-like growth factor, deficiency of, in juvenile chronic arthritis, 916–917
excess of, corticosteroid-induced, osteoporosis in, 315
replacement of, in glucocorticoid-induced osteoporosis, 323
Insurance, chiropractic and, 100–101
Interferon-t, *Tripterygium silfordii* Hook f effects on, 40
Interleukin(s), anti-inflammatory, 698–699
as giant cell arteritis markers, 510
as polymyalgia rheumatica markers, 510
hepatic effects of, 701–702
in bone loss, 573–574
in rheumatoid arthritis, 899
of elderly persons, 463–464
proinflammatory, 696–697
receptors for, anti-inflammatory activity of, 698–699
*Tripterygium silfordii* Hook f effects on, 40
Interleukin–1, overexpression of, in SLE, osteoporosis in, 313
response to, in Sjögren's syndrome, 931, 933
Interleukin–1-receptor antagonist, defects of, in SLE, 241
Interleukin–2, stimulation of, in SLE, 353
Interleukin–6, overexpression of, in SLE, 241
osteoporosis in, 313
response to, in Sjögren's syndrome, 933
Interleukin–10, overexpression of, in SLE, 239–240, 244
treatment based on, 394–395
Interphalangeal joints, of hand, gout of, 531–532
Ipraflavone, in osteoporosis, corticosteroid-induced, 322–323
Isometric exercises, for elderly persons, 635–636
Isotonic exercises, for elderly persons, 636–638
Iyengar yoga, 126–127
in osteoarthritis, 127–128

Juvenile chronic arthritis, 911–920
autonomic nervous system alterations in, 846, 918–920
cognitive-behavioral therapy for, 169
growth hormone abnormalities in, 916–917
hyperprolactinemia in, 722
hypothalamic-pituitary-adrenal axis in, 913–914
hypothalamic-pituitary-gonadal axis in, 917–918
prolactin abnormalities in, 914–915
stress in, 754–755
as provoking factor, 741–742
psychosocial functioning and, 753
Juvenile systemic lupus erythematosus, 920–921

*Kapha,* in Ayurvedic medicine, 134, 137
Ketoprofen, in elderly persons, pharmacokinetics of, 446–447
Kidney, drug elimination in, in elderly persons, 438–439
dysfunction of, in antiphospholipid syndrome, 334
transplantation in, 344
in SLE. See also *Nephritis, lupus.*
in antiphospholipid syndrome, 334
osteoporosis in, 313
predictors of, 208
treatment of, 364–365, 370–371
*Tripterygium silfordii* Hook f in, 38
Klinefelter's syndrome, systemic lupus erythematosus in, 958, 962

Knee, arthropathy of, in Milwaukee shoulder-knee syndrome, 543–544
meniscus of, changes of, osteoarthritis and, 555
injuries of, in elderly persons, 598–599
osteoarthritis of, electromagnetic fields in, 58
in elderly persons, **547–567**
cartilage changes in, 552–555
epidemiology of, 549–550
non-cartilaginous tissue changes in, 555–556
pathogenesis of, 556–557
risk factors for, 548, 550–552
treatment of, 557–565
in injury, 550
osteonecrosis of, in SLE, treatment of, 298–301
replacement of, in elderly persons, 606–607
Kyphosis, in elderly persons, 663–664

Laminectomy, in spinal stenosis, 602–603
Laxity, knee joint, osteoarthritis development in, 551
Leflunomide, in elderly persons, pharmacokinetics of, 442
Leukocytosis, in corticosteroid excess, 769–770
Leukopenia, cyclophosphamide-induced, 367
Leukotrienes, production of, glucocorticoid effects on, 861
Ligaments, changes of, osteoarthritis and, 555–556
Limb girdle dystrophy, in elderly persons, 662
Linkage analysis, in SLE, 232–233, 242–243
Lipid abnormalities, in SLE, 264–269
Lipid lowering agents, in elderly persons, myopathies induced by, 667
Lipoprotein (a), elevated levels of, in SLE, 268
Lipoprotein lipase deficiency, in SLE, 266
Livedo, in antiphospholipid syndrome, 334
Liver, drug metabolism in, in elderly persons, 436–438
function of, in inflammation, 701–702
Living wills, discussions on, 428–429
LJP 394 B-cell toleragen, in SLE, 392–393
Logarithm of odds score, for SLE, 233
Lubrication, in Ayurvedic medicine, 138
Lumbar spine, stenosis of, in elderly persons, 599–603
Lupus. See *Systemic lupus erythematosus.*
Lupus anticoagulant, in antiphospholipid syndrome, pregnancy outcome and, 335–336
prognosis and, 340
tests for, 336–337
in SLE, 208–209
thrombosis due to, 272
Lupus nephritis, predictors of, 208
treatment of, 391–393
cyclophosphamide in, 364–365
relapse after, 370–371
Luteinizing hormone, in juvenile chronic arthritis, 917
in juvenile systemic lupus erythematosus, 920–921
in testosterone regulation, 975
Lymphocytes. See also *B lymphocytes; T lymphocytes.*
apheresis of, 65
apoptosis of, in photopheresis, 76
estrogen effects on, 956–957
prolactin receptors on, 714

McKenzie method, 99
Macrophages, proinflammatory cytokines released from, 696–697
sex hormone effects on, 830–832
Magnetic fields, electric. See *Electromagnetic fields.*
permanent static magnets in, 58–59
Magnetic resonance imaging, of meniscal injuries, 598–599
of osteonecrosis, in SLE, 287, 289, 291
of rotator cuff disease, 596
of spinal stenosis, 600–602
Major histocompatibility complex, in SLE, 236–238
Manipulation, mechanisms of action of, 84–86
Mannose-binding protein, defects of, in SLE, 236
Manual techniques, **83–96**
chiropractic, 92–93, **97–102**
manipulation, 86–89
osteopathic, 84–86, 91–92
massage therapy, 84–86, 89–90
mechanisms of action of, 84–86
Massage therapy, 89–90
mechanisms of action of, 84–86
Meditation, in rheumatoid arthritis, 165
in yoga, 126
Medroxyprogesterone, in osteoporosis, 319
Melanocyte-stimulating hormone, anti-inflammatory activity of, 699
Meniscus, changes of, osteoarthritis and, 555
injuries of, in elderly persons, 598–599
Menstrual cycle disorders, in SLE, 313
Mesna, in cyclophosphamide toxicity protection, 369
Metacarpophalangeal joints, arthritis of, in hemochromatosis, 539

Metalloproteinases, in osteoarthritis pathogenesis, 556
Metatarsophalangeal joint, gout of, 529
Methimazole, in SLE, 398
Methotrexate, in elderly persons, in giant cell arteritis, 499
in polymyalgia rheumatica, 499
pharmacokinetics of, 440–442
in rheumatoid arthritis, 887–888
in SLE, osteoporosis due to, 313–314
Methoxypsoralen, in photopheresis, 75–76
Methylprednisolone, in elderly persons, in giant cell arteritis, 509
pharmacokinetics of, 449
in SLE, damage from, 207, 284
Milwaukee shoulder-knee syndrome, 543–544
Mind-body medicine, **161–176**
behavioral methods in, 164
biopsychosocial model of disease and, 162–164
in arthritis, 164–166
economic effects of, 171
outcome of, 166–169
in children, 169
in osteoarthritis, 170
in rheumatoid arthritis, 170–171
new developments in, 169–171
versus nonsteroidal anti-inflammatory drugs, 171–172
Minisatellite analysis, in SLE, 233
Mitochondrial myopathy, in elderly persons, 662–663
Monoclonal antibodies, in SLE, 245–247
3E10, 392
in complement inhibition, 393–394
in interleukin–10 inhibition, 394–395
T-lymphocyte inhibiting, 390–391
Monocytes, proinflammatory cytokines released from, 696–697
sex hormone effects on, 830–832
Monosodium urate, excess of. See also *Gout.*
epidemiology of, 528–529
Morning stiffness, in polymyalgia rheumatica, 493
Mortality, in SLE, bimodal pattern of, 258
Motor unit action potential measurement, in myopathies, in elderly persons, 652–653
Multiple sclerosis, hyperprolactinemia in, 718
Muscle disorders. See *Myopathies.*
Muscle weakness, corticosteroid-induced, osteoporosis in, 315
Muscular dystrophy, in elderly persons, 662
Musculoskeletal system, SLE manifestations in, 205–206
Myalgia, homeopathic treatment of, 119–121
Mycophenolate mofetil, in SLE, 397–398
Myelopathy, transverse, in SLE, cyclophosphamide effects on, 365
Myocardial infarction, in antiphospholipid syndrome, 334
in SLE, epidemiology of, 258–259
inflammation and, 271
risk factors for. See *Atherosclerosis, in SLE, risk factors for.*
Myopathies, in elderly persons, **647–672**
alcoholic, 667
amyloid, 665–666
axial, 663–664
dermatomyositis, 658–662
differential diagnosis of, 650–651
drug-induced, 666–667
endocrine, 664–665
evaluation of, 650–653
idiopathic inflammatory, 654–662
inclusion body, 655–658
mitochondrial, 662–663
muscular dystrophies, 662
polymyositis, 658–662
sarcopenia, 647–650
Myositis, in SLE, 205–206

Nabumetone, in elderly persons, pharmacokinetics of, 446
Nandrolone, in osteoporosis, 319
in rheumatoid arthritis, 886
in Sjögren's syndrome, 943
Naproxen, in elderly persons, pharmacokinetics of, 446–447
Necrosis, bone. See *Osteonecrosis.*
Nephritis, lupus, predictors of, 208
treatment of, 391–393
apheresis in, 67
cyclophosphamide in, 364–365
relapse after, 370–371
*Tripterygium silfordii* Hook f in, 38
Neuroendocrine-immune loop concept, in inflammation, 695–696, 705–708
Neuroendocrine manifestations, in ankylosing spondylitis, **969–987**
in chronic fatigue syndrome, 991–993, 996–998
in fibromyalgia, 990–996
in rheumatic disease, future research in, 1013–1014
gonadotropin-releasing hormone in, 725–729
inflammation, **693–711**
overview of, **1003–1017**
pediatric, **911–925**
prolactin in, 713–725
sex hormones in, **825–839**
stress, **737–763**
vascular endothelial system interactions with, **765–773**

Neuroendocrine manifestations *(Continued)*
in rheumatoid arthritis, autonomic nervous system interactions with, **841–857**
bone preservation and, **897–910**
in glucocorticoid therapy, **859–880**
in hormonal alterations, **805–823**
in pathogenesis, **775–803**
in sex hormone adjuvant therapy, **881–895**
in Sjögren's syndrome, **927–949**
in systemic lupus erythematosus, **951–968**
Neuroendoimmunology, in rheumatoid arthritis, 149–152
Neurologic changes, with age, sarcopenia in, 648
Neurophysiologic testing, in myopathies, in elderly persons, 652–653
Neurotransmitter production, in stress, 148–149
Nitric oxide production, estrogen effects on, 767–768
glucocorticoid effects on, 861–862
in inflammation, 704–705
Nonsteroidal anti-inflammatory drugs, in elderly persons, in calcium pyrophosphate dihydrate deposition disease, 543
in gout, 535–536
in osteoarthritis, 560–562
in polymyalgia rheumatica, 499
in rheumatoid arthritis, 524
in systemic lupus erythematosus, 484
pharmacokinetics of, 445–448
versus mind-body medicine, 171–172
Norepinephrine, in inflammation, 844
Nuclear medicine, in osteonecrosis, in SLE, 289–291
Nulliparity, rheumatoid arthritis risk in, 806
Nutrition, in elderly persons, assessment of, 426–427
in osteoarthritis, 562–563

Obesity, osteoarthritis in, 550, 559–560
Oculopharyngeal dystrophy, in elderly persons, 662
Oral contraceptives, in rheumatoid arthritis, 792–793, 810–811, 888
Orthoses, in osteoarthritis, 89
Osteoarthritis, acupuncture in, 105–107, 110–111
electromagnetic fields in, 58
glucosamine in, **1–11**
herbal preparations in, 16–17, 19–23
homeopathic treatment of, 120–121
in elderly persons, **547–567**
cartilage changes in, 552–555
epidemiology of, 549–550
exercise for, 624, 626–629
non-cartilaginous tissue changes in, 555–556
pathogenesis of, 556–557
risk factors for, 548, 550–552
treatment of, 557–565
versus rheumatoid arthritis, 522–523
manipulation for, 86, 88
mind-body medicine in, 170
yoga in, 127–130
Osteoblasts, age effects on, osteoporosis and, 571–572
suppression of, corticosteroid-induced, osteoporosis in, 314
Osteocalcin, measurement of, in osteoporosis, in SLE, 316
Osteoclasts, age effects on, osteoporosis and, 571–572
estrogen effects on, 832–834
excess of, corticosteroid-induced, osteoporosis in, 315
Osteomalacia, in elderly persons, 665
Osteonecrosis, in SLE, **279–309**
asymptomatic, 293–294
coagulopathy in, 284–285
corticosteroid-induced, 282–284
diagnosis of, 285–291
diseases associated with, 281–282
future considerations in, 303
incidence of, 280
multifocal, 302
pathogenesis of, 280
pathology of, 280–281
risk factors for, 281–285
staging of, 287, 289
treatment of, 292–302
in ankle, 302
in knee, 298–301
in shoulder, 302
nonoperative, 292–294
planning for, 302–303
postcollapse, 296–297
precollapse, 294–296
Osteopathic manipulation, 84–86, 91–92
Osteoporosis, in elderly persons, **569–591**
bone mass versus age, 572
bone remodeling and, 571–572
corticosteroid-induced, 450, 524
definition of, 569–570
diagnosis of, 575–577
epidemiology of, 570–571
in androgen deficiency, 574–575
in calcium imbalance, 572–573
in estrogen deficiency, 573–574
pathogenesis of, 572–575
risk factors for, 575
secondary causes of, 575–576
treatment and prevention of, 575–584

bisphosphonates in, 579–580, 582
calcitonin in, 582–583
calcium in, 578
estrogen replacement in, 578–579
exercise in, 577–578
in men, 583–584
selective estrogen receptor antagonists in, 582
vitamin D in, 578
in rheumatoid arthritis, **897–910**
in SLE, corticosteroid-induced, 208, **311–329**
assessment of, 315–316
characteristics of, 311–312
dehydroepiandrosterone effects on, 357–358
mechanisms of, 314–315
risk factors for, 312–314
treatment of, 316–323
Osteotomy, in osteonecrosis, in SLE, 295
Ovarian failure, cyclosphosphamide-induced, 368

Pain, bone, in osteonecrosis, in SLE, 286
in elderly persons, diffuse syndromes of, 679–680. See also *Fibromyalgia; Polymyalgia rheumatica.*
in calcium pyrophosphate dihydrate deposition disease, 540
in giant cell arteritis, 501, 504
in gout, 529
Pain management, acupuncture in, 103–115
Ayurvedic medicine in, 133–144
back, chiropractic in, 99
education in, 152–156
electromagnetic fields in, 57–58
exercise in, 152–156
glucosamine therapy in, 1–11
homeopathy in, 117–123
manual techniques in, 83–96
mechanisms and, 146
phyto–anti-inflammatory agents in, 13–27
spiritual activity in, 177–187
stress modification in, 152–156
*Tripterygium silfordii* Hook f in, 29–50
yoga in, 125–132
Pamidronate, in osteoporosis, 320–321
Parathyroid hormone, excess of, osteoporosis in, 572–573
in osteoporosis, corticosteroid-induced, 322
Parthenolide, as anti-inflammatory agent, 16, 20–21, 24
Pediatric patients, ankylosing spondylitis in, neuroendocrine changes in, 921
rheumatoid arthritis in. See *Juvenile chronic arthritis.*
systemic lupus erythematosus in, neuroendocrine changes in, 920–921
Pentoxifylline, in SLE, 244
Peptic ulcer disease, glucocorticoid-induced, 870–871
Peripheral vascular disease, in antiphospholipid syndrome, 334
Personality, in rheumatoid arthritis, 747–748
Pharmacodynamics, in elderly persons, 435
Pharmacokinetics, in elderly persons, 434–439
Pharmacology. See *Drugs.*
Phenylbutazone, in elderly persons, pharmacokinetics of, 446
Phospholipid-binding proteins, SLE antibody recognition of, 219–220
Photopheresis, **75–81**
adverse effects of, 76
description of, 75–76
future of, 79–80
in rheumatoid arthritis, 77–78
in systemic lupus erythematosus, 76–77
in systemic sclerosis, 78–79
Physical therapy, for inclusion body myopathies, 656
for knee osteoarthritis, 558–560
for osteonecrosis, in SLE, 292
for spinal stenosis, 602
Phyto–anti-inflammatory agents, review of, **13–27**
*Tripterygium silfordii* Hook f, **29–50**
Phytodolor, as anti-inflammatory agent, 16–17, 21–22
Piroxicam, in elderly persons, pharmacokinetics of, 446
*Pitta*, in Ayurvedic medicine, 134, 137
Pituitary gland. See also *Hypothalamic-pituitary*-specific organ *axis.*
dysfunction of, corticosteroid-induced, osteoporosis in, 314
Pizoelectric effect, in bone growth and repair, 52–53
Plant-based agents, anti-inflammatory, review of, **13–27**
*Tripterygium silfordii* Hook f, **29–50**
in Ayurvedic medicine, 138–140
Plasmapheresis. See *Apheresis.*
Plasminogen activator inhibitor 1, elevated levels of, in SLE, 272
Pneumonitis, in elderly persons, in systemic lupus erythematosus, 477, 485
Polyarteritis nodosa, apheresis in, 70
Polymyalgia rheumatica, in elderly persons, 493–500, 510–511, 679
autoimmune aspects of, 495
clinical features of, 497, 679
definition of, 493–494

Polymyalgia rheumatica *(Continued)*
diagnosis of, 497–498
epidemiology of, 494
giant cell arteritis with, 494, 497
markers of, 510–511
pathophysiology of, 494–497
prognosis for, 511
treatment of, 498–500
versus fibromyalgia, 679
versus rheumatoid arthritis, 522
Polymyositis, apheresis in, 70
in elderly persons, 658–662
Polypharmacy syndrome, in elderly persons, 427
*Populus tremula*, in Phytodolor, 16–17, 21–22
Postpolio syndrome, pain in, static magnet treatment of, 59
Postures, in yoga, 126–127
Prayer and spirituality, **177–187**
case study illustrating, 177–178
clinical effects of, 179–180
mechanisms of, 181–182
healing and, 178–179
intercessory, clinical effects of, 179–180
medical effects of, 181
physician addressing, 182–183
psychologic problems and, 180–181
quality of life concerns and, 180–181
Prednisolone, in elderly persons, pharmacokinetics of, 449
in SLE, atherosclerosis development and, 267
osteonecrosis development and, 281, 283
Prednisone, in elderly persons, in giant cell arteritis, 508–509
in gout, 536
in polymyalgia rheumatica, 499
pharmacokinetics of, 449
in SLE, atherosclerosis development and, 267
damage from, 207–208
dehydroepiandrosterone with, 355–356
Pregnancy, apheresis in, 68
in ankylosing spondylitis, 971
in antiphospholipid syndrome, 335–336, 342–344
in rheumatoid arthritis, 806–809
in SLE, flare in, 312–313
Pro-opiomelanocortin, anti-inflammatory activity of, 699
Probenecid, in elderly persons, in gout, 538
Progesterone, in pregnancy, 807–809
in rheumatoid arthritis, 519–520, 810–812
in Sjögren's syndrome, 934–938
in systemic lupus erythematosus, 957–958
replacement of, in osteoporosis, 318–319
Progestogens, in systemic lupus erythematosus, 957–958
Prolactin, 713–725
excess of. See *Hyperprolactinemia.*
immune system interactions with, 714–717
in rheumatoid arthritis, 150–153, 155, 809–810
in stress, 148–150
in systemic lupus erythematosus, 960–961
production of, in inflammation, 697, 703
receptors for, 714
Proprioception, defects of, osteoarthritis development in, 551
training for, in osteoarthritis, 88–89
Prostaglandins, inhibition of, *Tripterygium silfordii* Hook f in, 41–42
production of, glucocorticoid effects on, 861
Proteins, pathogenic, apheresis of, 66
Proteoglycans, in cartilage, changes in, osteoarthritis and, 552–555
Pseudogout. See *Calcium pyrophosphate dihydrate deposition disease (pseudogout).*
Psychiatric disorders, in Sjögren's syndrome, 928–929
in SLE, cyclophosphamide effects on, 365
Psychologic problems, in rheumatoid arthritis, prayer effects on, 180–181
Psychosocial factors, in chronic disease, 162–164
Pulmonary embolism, in antiphospholipid syndrome, treatment of, 344
Pulsed electromagnetic fields, cartilage effects of, 55–57
clinical applications of, 57–58
in bone healing, 54–55
Purpura, thrombotic thrombocytopenia, apheresis in, 65, 70

Quadriceps exercise, for knee osteoarthritis, 559
Quality of life, in rheumatoid arthritis, prayer effects on, 180–181
Quinacrine, in elderly persons, in systemic lupus erythematosus, 485
Quinagolide, in hyperprolactinemia, in rheumatoid arthritis, 721

Radiography, in osteonecrosis, in SLE, 286–288
Radionuclide studies, in osteonecrosis, in SLE, 289–291
Radius, fractures of, in elderly persons, 610–611

Raloxifene, in osteoporosis prevention and treatment, 582
in rheumatoid arthritis, 901
Range of motion exercises, for elderly persons, 633–634
*Rasayana*, in Ayurvedic medicine, 140
Rash, in systemic lupus erythematosus, in elderly persons, 477
Raynaud's phenomenon, in SLE, 205
Reactive, arthritis hyperprolactinemia in, 719–720
Relative risk, for SLE, 233
Relaxation, in rheumatoid arthritis, 165
Religious beliefs and practices. See *Prayer and spirituality.*
Remitting seronegative symmetrical synovitis with pitting edema, in elderly persons, versus rheumatoid arthritis, 522–523
Reproductive system, *Tripterygium silfordii* Hook f effects on, 44
Retinopathy, in antiphospholipid syndrome, 334
Rheumatoid arthritis, apheresis in, 65, 68–69
autonomic-neuroendocrine-immune system interactions in, **841–857**
adrenergic receptors, 847–848
background of, 842–843
catecholamines, 848–849
clinical aspects of, 845–846
hypothalamic-pituitary-adrenal axis, 849–850
mechanisms of, 844–845
Ayurvedic medicine in, 140–142
bone cells in, estrogen effects on, 832–834
bone loss in, **897–910**
disease-specific mechanisms in, 899
glucocorticoid-induced, 903–907
hormonal factors in, 899–902
pathophysiology of, 897–902
treatment of, 902–907
cortisol production in, 862–863
glucocorticoid therapy for, 813–816, **859–880**
bone loss in, 901–907
clinical consequences of, 867
dosages for, 867–870, 872–873
factors influencing, 862–866
high dosages in, 868–870
low dosages in, 867–868
mechanisms of, 859–862
modular theory of, 866
optimizing, 872–875
receptor action in, 859–860
resistance to, 864–866
sex hormones and, 863–864
side effects of, 870–873
spontaneous glucocorticoid production and, 862–863
timing of, 873
types of, 874–875
herbal preparations in, 15–16, 18–23
homeopathic treatment of, 119–121
hormonal alterations in, **805–823**
androgens, 812–813, 899–901, 903, 918
estrogen, 810–812, 901–903, 917–918
hypothalamic-pituitary adrenal axis, 150, 813–815, 849–850, 913–914, 935
in breast-feeding, 806–809
in pregnancy, 806–809
postpartum, 806–809
progesterone, 519–520, 810–812
prolactin, 150–153, 155, 809–810
hyperprolactinemia in, 719–721
hypothalamic-pituitary-adrenal axis in, 935
in elderly persons, **517–526**
clinical manifestations of, 520–521
comorbid conditions with, 520
course of, 522
differential diagnosis of, 522–524
exercise for, 618–624
genetic factors in, 519
hormones in, 519–520
immunosenescence in, 518–519
prognosis for, 521–522
seronegative, 679
treatment of, 524–525
versus early-onset rheumatoid arthritis, 517–521
in pediatric patients. See *Juvenile chronic arthritis.*
in pregnancy, 806–809
juvenile. See *Juvenile chronic arthritis.*
mind-body medicine in, 163–168
new developments in, 170–171
versus nonsteroidal anti-inflammatory drugs, 171–172
neuroendoimmunology in, 149–152
photopheresis in, 77–78
prayer and spirituality in, 180
case study of, 177–178
psychologic problems and, 180–181
quality of life and, 180–181
preclinical phase of, 776
risk factors for, **775–803**
adrenal androgen levels, 788–792
age, 784–787
core system involvement in, 779–782
dehydroepiandrosterone sulfate levels, 787–790
environmental conditions, 786–787
epidemiologic considerations in, 783–784
gender, 784–787
general, 796–797
genetic, 778, 783–784, 786–787
glucocorticoid levels, 788–789

Rheumatoid arthritis *(Continued)*
immunologic, 794–795
in men, 795–796
integrative physiopathogenetic paradigm for, 776–778
judgmental criteria, 783
neuroendocrine, 794–795
oral contraceptives, 792–793
rheumatoid factor, 793–794
sex hormone levels, 787–788
study quality assessment, 781, 783
sex hormones in, as adjuvant therapy, **881–895**
androgens, 886–888
estrogens, 888–889
future of, 889–890
mechanisms of, 884–885
principles of, 882–884
as risk factor, 787–788
in elderly persons, 519–520
juvenile, 917–918
stress in. See *Stress, rheumatoid arthritis and.*
thyroiditis in, 941
treatment of, glucocorticoids in. See *Rheumatoid arthritis, glucocorticoid therapy for.*
sex hormones in, **881–895**
*Tripterygium silfordii* Hook f in, 34–36, 39
Rheumatoid factor, in rheumatoid arthritis, 793–794
*Ribs nigri folium*, as anti-inflammatory agent, 24
Risedronate, in osteoporosis prevention and treatment, 320–321, 580, 582, 905–906
Rofecoxib, in elderly persons, in gout, 536
in osteoarthritis, 562
pharmacokinetics of, 447
Rotator cuff disease, in elderly persons, 593–597

Safety, of acupuncture, 108–109
of electromagnetic fields and magnets, 59–60
of yoga, 129
Salicin, as anti-inflammatory agent, 16, 20, 24
Salicylates, in elderly persons, in osteoarthritis, 561
Salivary glands, sex hormone effects on, in Sjögren's syndrome, 937–938
Sarcopenia, 647–650
Scintigraphy, in osteonecrosis, in SLE, 289–291
Scleroderma, hyperprolactinemia in, 719–720
photopheresis in, 78–79
*Tripterygium silfordii* Hook f in, 38
Sedentary life style, in SLE, as atherosclerosis risk factor, 269
Selective androgen receptor modulators, in ankylosing spondylitis, 982
Selective estrogen receptor antagonists, in osteoporosis prevention and treatment, 582
in rheumatoid arthritis, 901
Selective serotonin reuptake inhibitors, in fibromyalgia, 996
Separators, for apheresis, 66
Serositis, in systemic lupus erythematosus, in elderly persons, 477
Serotonin, in chronic fatigue syndrome, 997–998
in fibromyalgia, 995–996
Sex hormones. See also *Androgens; Estrogen(s);* specific hormones.
in ankylosing spondylitis, **969–987**
in autoimmune disease susceptibility, **825–839**
B lymphocytes, 826–829
bone cells, 832–834
indirect effects of, 834–835
monocytes and macrophages, 830–832
T lymphocytes, 829–830
in fibromyalgia, 995
in rheumatoid arthritis. See *Rheumatoid arthritis, sex hormones in.*
in Sjögren's syndrome, 934–938, 943
in systemic lupus erythematosus. See *Systemic lupus erythematosus, sex hormones in.*
synthesis of, 882–883
Sexual function, *Tripterygium silfordii* Hook f effects on, 44
Shoulder, arthropathy of, in Milwaukee shoulder-knee syndrome, 543–544
osteonecrosis of, in SLE, treatment of, 302
replacement of, 607–608
rotator cuff disease of, 593–597
Sib-pair analysis, in SLE, 232–233
Simvastatin, in elderly persons, myopathies induced by, 667
Single photon emission computed tomography, in atherosclerosis, in SLE, 210, 261–262
Sjögren's syndrome, **927–949**
behavioral profile of, 928–929
description of, 927–928
hyperprolactinemia in, 719
hypothalamic-pituitary-adrenal axis in, 929–935, 942
hypothalamic-pituitary-gonadal axis in, 934–938
hypothalamic-pituitary-thyroid axis in, 934, 938–941
in systemic lupus erythematosus, in elderly persons, 477

psychiatric profile of, 928–929
treatment of, future, 941–943
Skin, antiphospholipid syndrome manifestations in, 334
SLE manifestations in, ultraviolet light and, 217
SLE. See *Systemic lupus erythematosus.*
Social assessment, of elderly persons, 427–428
Sodium fluoride, in osteoporosis, corticosteroid-induced, 321–322
Soft tissue, swelling of, in systemic lupus erythematosus, in elderly persons, 477
*Solidago virgaurea,* in Phytodolor, 16–17, 21–22
Somatostatin, anti-inflammatory activity of, 699
in fibromyalgia, 995
Spine, fractures of, in elderly persons, 612
stenosis of, in elderly persons, 599–603
Spirituality. See *Prayer and spirituality.*
Spondyloarthropathies, seronegative, versus rheumatoid arthritis, in elderly persons, 522
Spouses, participation in mind-body medicine, 170
Stanozolol, in osteonecrosis, in SLE, 293
Statin drugs, in elderly persons, myopathies induced by, 667
Stem cell transplantation, in SLE, **377–387**, 395
allogeneic, results of, 381
animal studies of, 380–381
autologous, 378–379
cyclophosphamide immunoablation before, 383–385
results of, 381–383
conditioning regimens for, 379–380
cyclophosphamide role in, 371, 383–385
description of, 377–378
donors for, 378
types of, 378–379
Steroid hormones. See also *Sex hormones.*
in SLE, genetic aspects of, 241–242
Stoop test, for spinal stenosis, 600
Streaming potentials, in bone growth and repair, 53–54
Strength testing, in myopathies, 650–652
in rotator cuff disease, 595–596
Strength training, for elderly persons, 635–638, 649–650
Stress, **737–763**. See also *Inflammation.*
chronic fatigue syndrome and, 991, 993
estrogen in, 834–835
fibromyalgia and, 749–751, 754–755, 990–991
hormones produced in, immunity and, 148–149
juvenile chronic arthritis and, 754–755
as provoking factor, 741–742
psychosocial functioning and, 753
management of, in rheumatoid arthritis, 152–156, 166
yoga in, 126
mechanisms of, 147–148
neuroendocrine-immune system interactions with, 756–757
rheumatoid arthritis and, 149–152, 846
as provoking factor, 739–741
coping with, 751–752
major, 746–747, 754–755
measurement of, 738–739
minor, 743–746, 754–755
personality and, 747–748
psychosocial functioning and, 752–753
treatment of, 753–754
Sjögren's syndrome and, 929
systemic lupus erythematosus and, 748–749, 754–755
psychosocial functioning and, 752–753
Stretching exercises, for elderly persons, 634
Stroke, in antiphospholipid syndrome, 333–334
in giant cell arteritis, 504
in SLE, in hyperhomocysteinemia, 270
Substance P, in inflammation, 698
Sulfasalazine, in elderly persons, pharmacokinetics of, 443
Sulfinpyrazone, in elderly persons, in gout, 538
Sulindac, in elderly persons, pharmacokinetics of, 446
Support systems, for elderly persons, assessment of, 427–428
Sweating, in Ayurvedic medicine, 138
Sympathetic-adrenal-medullary system, in stress, 147–148
Sympathetic nervous system dysfunction, in juvenile chronic arthritis, 918–920
Synovial fluid, examination of, in basic calcium phosphate-hydroxyapatite deposition disease, 544
in calcium pyrophosphate dihydrate deposition disease, 540–541
monosodium urate crystals in, 534. See also *Gout.*
Synovitis, in polymyalgia rheumatica, 494–495
remitting seronegative symmetrical, with pitting edema, versus rheumatoid arthritis, 522–523
Systemic lupus erythematosus, antiphospholipid syndrome in, **331–348**
apoptosis in, **215–227**, 246
atherosclerosis in, 209–210, **257–278**
damage in, 206–210
disease activity in, 203–204

Systemic lupus erythematosus *(Continued)*
educational level and, 202
environmental triggers of, 203
epidemiology of, 199–203
ethnic differences in, 201
evolution of, 204–205
flare in, in pregnancy, 312–313
patterns of, 203–204
ultraviolet light and, 217
gender differences in. See *Gender differences, in SLE.*
genetics of, **229–256**
health status in, 210–211
Hopkins Lupus Cohort study of, **199–213**
hyperprolactinemia in, 722–723, 725
hypothalamic-pituitary-gonadal axis in, 920–921
in elderly persons, **475–492**
clinical features of, 477–478
diagnosis of, 483–484
epidemiology of, 476–477
immune response in, 479–483
radiographic features of, 477, 479
treatment of, 484–487
in pediatric patients, neuroendocrine changes in, 920–921
marital status and, 202–203
mortality in, bimodal pattern of, 258
organ system involvement in, 205–206
osteonecrosis in, **279–309**
osteoporosis in, 208, **311–329**
pathogenesis of, estrogen in, 766
gonadotropin-releasing hormone in, 726
pathophysiology of. See also *Apoptosis, in SLE; Genetics, of SLE.*
prolactin in, 715
photopheresis in, 76–77
pregnancy in, flare in, 312–313
prolactin and, 920, 960–961
relative risk for, 233
self-help program for, 167
sex hormones in, **951–968**
animal models of, 953–955
B lymphocyte effects of, 826–827
exogenous, 962–963
immune function and, 955–958
in Klinefelter's syndrome, 958, 962
in males, 961–962
juvenile, 920–921
macrophage effects of, 831
mechanisms of action of, 952–953
sexual dimorphism in, 952
smoking and, 201–202
stress and, 748–749, 754–755
psychosocial functioning and, 752–753
thrombosis in. See *Thrombosis, in SLE.*
thyroiditis in, 941
treatment of, 2-chlorodeoxyadenosine in, 397
anti–interleukin–10 antibodies in, 244
antimalarial drugs in, 267–268
apheresis in, 65–68
AS101 in, 396–397
bindarit in, 398
biologic agents in, 390–395
bromocriptine in, 244–245, 400–401
complement replacement in, 244
corticosteroids in. See *Corticosteroids, in SLE.*
cyclophosphamide in, **363–375**
damage from, 207–208
dehydroepiandrosterone in, 244–245, **349–362,** 399–400
genetic considerations in, 239, 243–247
hormones in, 398–401. See also *Dehydroepiandrosterone and dehydroepiandrosterone sulfate.*
methimazole in, 398
mycophenolate mofetil in, 397–398
new, **389–406**
pentoxifylline in, 244
stem cell transplantation in, 371, **377–387,** 395
T-lymphocyte inhibitors in, 390–391
thalidomide in, 244, 396
*Tripterygium silfordii* Hook f in, 35–36
Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, 200, 206–207
Systemic sclerosis, photopheresis in, 78–79
*Tripterygium silfordii* Hook f in, 38

T-cell receptor defects, in SLE, 239
T lymphocytes, apoptosis of, glucocorticoid effects on, 862
catecholamine effects on, 849
in SLE, 238–241
antigen response of, 216–217
dehydroepiandrosterone effects on, 353
inhibitors of, 390–391
treatments based on, 246
of elderly persons, 457–459
as polymyalgia rheumatica markers, 510
in giant cell arteritis, 495–496
in systemic lupus erythematosus, 479–482
response of, in inflammation, 700–701
sex hormone effects on, 829–830
Takayasu's arteritis, pathogenesis of, estrogen in, 766
versus giant cell arteritis, 502–503
Tamoxifen, in osteoporosis prevention and treatment, 582
*Tanacetum parthenium* (feverfew), as anti-inflammatory agent, 16, 20–21, 24

Taping, for knee osteoarthritis, 560
Te chi, in acupuncture, 104, 107–108
Telomere senescence, in elderly persons, 464–465
Temporal arteritis. See *Giant cell (temporal) arteritis.*
Ten commandments, of rheumatology, for elderly persons, 429–431
Tendons, changes of, osteoarthritis and, 555–556
Tenidap, in elderly persons, in polymyalgia rheumatica, 499–500
Terpenoids, in *Tripterygium silfordii* Hook f, 31–34
Testicular failure, cyclosphosphamide-induced, 368
Testosterone, binding of, in ankylosing spondylitis, 977–978
  deficiency of, osteoporosis in, 574–575
  in ankylosing spondylitis. See *Ankylosing spondylitis, sex hormones in.*
  in autoimmune disease susceptibility, B lymphocytes, 827–829
    monocytes and macrophages, 831–832
    T lymphocytes, 830
  in rheumatoid arthritis, 812–813
    bone loss and, 899–901, 903
    juvenile, 918
  in Sjögren's syndrome, 934–938
  in systemic lupus erythematosus, 955–956, 960, 962
    juvenile, 921
  regulation of, 973–975
  replacement of, in osteoporosis prevention and treatment, 319, 583–584
    in rheumatoid arthritis, 885–888, 903
  vascular endothelial system effects of, 768–769
Thalidomide, in SLE, 244, 396
Thiazide diuretics, in osteoporosis, 906–907
Thoracolumbar kyphosis of the elderly, 663–664
Thrombocythemia, in SLE, 284
Thrombocytopenia, in antiphospholipid syndrome, 335, 344
  in SLE, 284, 365–366
    in elderly persons, 485
Thromboembolism, in total hip replacement, 604–606
  in total knee replacement, 607
Thrombosis, in SLE, 208–209
    in antiphospholipid syndrome, 332–334
      prognosis and, 340
      treatment of, 342
    in hyperhomocysteinemia, 270
    mechanisms of, 271–272
Thrombotic thrombocytopenia purpura, apheresis in, 65, 70
Thymosin fraction 5, in Sjögren's syndrome, 943
Thymus, estrogen effects on, 829
  of elderly persons, 457
Thyroid gland, disease of, myopathies in, in elderly persons, 664–665
  function of, in Sjögren's syndrome, 934, 938–941
  suppression of, in inflammation, 703
Thyroid-stimulating hormone, response to, in fibromyalgia, 995
Thyroiditis, autoimmune, in Sjögren's syndrome, 939–941
Tiaprofenic acid, in elderly persons, pharmacokinetics of, 446
Tissue plasminogen activator, elevated levels of, in SLE, 284
Tolmetin, in elderly persons, pharmacokinetics of, 446
Tophi, in gout, 529, 532–533
Total joint replacement, in elderly persons, hip, 603–606
    knee, 606–607
    shoulder, 607–608
Tramadol, in elderly persons, in osteoarthritis, 561
    in systemic lupus erythematosus, 484–485
Transforming growth factor-b, excess of, corticosteroid-induced, osteoporosis in, 315
Transplantation, kidney, *Tripterygium silfordii* Hook f in, 38
  stem cell. See *Stem cell transplantation.*
Transverse myelopathy, in SLE, cyclophosphamide effects on, 365
Triamcinolone, in elderly persons, in calcium pyrophosphate dihydrate deposition disease, 543
    in gout, 536
Tridosha theory, in Ayurvedic medicine, 134, 138
Triglycerides, elevated levels of, in SLE, 266
Tripchlorolide, 31, 34
Tripdiolide, 31–33
*Tripterygium silfordii* Hook f, **29–50**
  adverse effects of, 38–39
  chemistry of, 30–34
  clinical studies of, 34–39
  mechanism of action of, 30, 40–44
    animal studies of, 42–43
    on cellular immune response, 40
    on humoral immune response, 40–41
    on pituitary-adrenal axis, 43–44
    on proinflammatory mediators, 41–42
    on reproductive system, 44
  preparations of, 30
  toxicity of, 44–45
Triptolide, 31–35
Triptonide, 31–33
Triptophenolide, 32–33

Triptriolide, 31
Tumor necrosis factor-a, in osteoporosis pathogenesis, 573–574
in rheumatoid arthritis, 899
overexpression of, in SLE, 240–241, 244
osteoporosis in, 313
receptor for, anti-inflammatory activity of, 698–699
Tumor necrosis factor inhibitors, in elderly persons, pharmacokinetics of, 448–449

Ultrasonic devices, in osteonecrosis, in SLE, 292
Ultrasonography, in giant cell arteritis, 508
Ultraviolet light, in photopheresis, 75–76
in SLE flares, antigen redistribution and, 217
Uric acid and urates, excess of. See also *Gout*.
epidemiology of, 528–529
Urinary retention, in total hip replacement, 604
*Urtica dioica*, as anti-inflammatory agent, 23–24

Valvular heart disease, in antiphospholipid syndrome, 336
Vascular endothelial system, in inflammation, **765–773**
androgen effects on, 768–769
estrogen effects on, 766–768
glucocorticoid effects on, 769–771
in rheumatoid arthritis, 779
Vasculitis, gastrointestinal, in SLE, cyclophosphamide effects on, 366
temporal. See *Giant cell (temporal) arteritis*.
Vasculopathy, in antiphospholipid syndrome, 333
Vasodilators, in osteonecrosis, in SLE, 293
Vasopressin, deficiency of, in chronic fatigue syndrome, 997
immunomodulatory effects of, 698
production of, in inflammation, 703
*Vata*, in Ayurvedic medicine, 134, 137
Vertebral fractures, in elderly persons, 612
Viral infections, versus rheumatoid arthritis, in elderly persons, 522
Visual loss, in giant cell arteritis, 501, 504–505
Vitamin(s), supplementation with, in osteoarthritis, in elderly persons, 562–563
Vitamin D, deficiency of, osteoporosis in, 573
in SLE, 312
measurement of, in osteoporosis, in SLE, 316
supplementation with, in osteoporosis prevention and treatment, 317–318, 578, 583–584, 905
von Willebrand factor, as giant cell arteritis marker, 511
as polymyalgia rheumatica marker, 511

Walking program, for knee osteoarthritis, 559
Warfarin, in antiphospholipid antibodies, 341
in antiphospholipid syndrome, 342
Weakness, muscle. See also *Myopathies*.
osteoarthritis development in, 550–551, 556
Weight bearing, reduction of, in osteonecrosis, in SLE, 292
Willow bark extract, as anti-inflammatory agent, 16, 20
*Withania somnifera*, in Ayurvedic formulation, as anti-inflammatory agent, 22
Wolff's Law, in bone growth and repair, 52–53
Wrist, fractures of, in elderly persons, 610–611

Yoga, **125–132**
definition of, 125
in osteoarthritis, 127–130
principles of, 125–126
prospective controlled studies of, 128–129
referral to, 130–131
risks of, 129
styles of, 126–127
westernization of, 126